Cargando…
Identification of lncRNA FAM83H-AS1 as a novel prognostic marker in luminal subtype breast cancer
BACKGROUND: Luminal subtype breast cancer accounts for a predominant number of breast cancers. Considering the heterogeneity of the disease, it is urgent to develop novel biomarkers to improve risk stratification and optimize therapy choices. Long non-coding RNA (lncRNA) represents an emerging and u...
Autores principales: | Yang, Fan, Lv, Shi-Xu, Lv, Lin, Liu, Ye-Huan, Dong, Si-Yang, Yao, Zhi-Han, Dai, Xuan-xuan, Zhang, Xiao-Hua, Wang, Ou-Chen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117955/ https://www.ncbi.nlm.nih.gov/pubmed/27895496 http://dx.doi.org/10.2147/OTT.S110055 |
Ejemplares similares
-
The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis
por: Yang, Qin, et al.
Publicado: (2020) -
LncRNA FAM83A‐AS1 promotes lung adenocarcinoma progression by enhancing the pre‐mRNA stability of FAM83A
por: Wang, Wenyi, et al.
Publicado: (2021) -
LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect β-catenin from degradation
por: Zhou, Min, et al.
Publicado: (2022) -
FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
por: Richtmann, Sarah, et al.
Publicado: (2019) -
FAM83A and FAM83A-AS1 both play oncogenic roles in lung adenocarcinoma
por: Wang, Gaoming, et al.
Publicado: (2021)